UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines
Category: #health  By Pankaj Singh  Date: 2020-07-20
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines

Even though the COVID-19 vaccine hasn’t been launched worldwide, it seems that leading nations are competing over who will have first access once a vaccine is ready. Recently, the government of the UK has reportedly signed an agreement with Pfizer Inc. and BioNTech SE, leading pharmaceutical companies developing a vaccine against COVID-19, to supply 30 million doses of m-RNA based vaccine candidates being developed under BNT162 program.

Sources cite that the company’s experimental vaccine candidates are currently in development and are subject to regulatory approval. The terms and conditions of the deal were based on the volume of doses and timing of delivery.

For the record, the BNT162 program leverages BioNTech’s mRNA technology and is supported by Pfizer’s vaccine development and manufacturing capabilities. The vaccine candidates are currently undergoing clinical trials and not presently authorized for distribution across the world. Both companies are using pre-clinical and clinical data to decide the future course of vaccine development.

Also, both companies are currently evaluating the minimum four potential vaccines, each of which represents a unique combination of mRNA format and target antigen. BioNTech and Pfizer previously announced the preliminary outcomes from BNT162b1, the most advanced mRNA formulations.

The data showed that BNT162b1 can produce neutralizing antibodies in humans at or above the levels detected in the plasma from COVID-19 recovered patients at relatively low dose levels.

Both companies are planning to commence Phase 2b/3 efficiency and safety trials later this month. If studies are successful, Pfizer and BioNTech will seek Conditional Marketing Authorization and regulatory review until October 2020. Both companies aim to produce up to 100 mn doses by 2020 and over 1.3 bn doses by the end of 2021.

For the record, SARC-COV-2 has infected over 14 million and took the lives of 0.8 million people across the globe, and the effective vaccine seems to be the only way that can put an end on the pandemic.

Source - https://www.businesswire.com/news/home/20200719005057/en/Pfizer-BioNTech-Announce-Agreement-United-Kingdom-30



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Debenhams announces plans to close its remaining shops on 15th May

Debenhams announces plans to close its remaining shops on 15th May

By Pankaj Singh

Debenhams, a department store company, has reportedly announced the closure of its remaining 49 stores by 15th May, shutting more than 200 years of trade on the UK high streets.

Tricol enters sales & marketing agency agreement with NorthStar

Tricol enters sales & marketing agency agreement with NorthStar

By Pankaj Singh

Tricol Biomedical, a fully integrated medical devices company, has recently announced a sales & marketing agency agreement with NorthStar Sales Alliance for its hemostatic products. The deal will take immediate eff...

T-ROC unites with Conversity to enhance online shopping experience

T-ROC unites with Conversity to enhance online shopping experience

By Pankaj Singh

The Revenue Optimization Companies (T-ROC) has reportedly announced its partnership with Conversity, the IGS (Intelligent Guided Selling) platform creator. This partnership was entered in a bid to enhance the in-store ...